Lupin has received approval for its Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Diprolene Ointment, 0.05%, of Merck Sharp and Dohme Corp. The product will be manufactured at company's Pithampur Unit 3 facility, India. Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, (RLD: Diprolene) had an annual sales of approximately $ 22 million in the U.S. (IQVIA MAT September 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
